- Report
- June 2025
- 150 Pages
Global
From €2403EUR$2,699USD£2,076GBP
- Report
- June 2025
- 200 Pages
Global
From €2483EUR$2,789USD£2,145GBP
- Drug Pipelines
- June 2025
- 200 Pages
Global
From €2483EUR$2,789USD£2,145GBP
- Drug Pipelines
- June 2025
- 200 Pages
Global
From €2483EUR$2,789USD£2,145GBP
- Drug Pipelines
- June 2025
- 200 Pages
Global
From €2483EUR$2,789USD£2,145GBP
- Report
- June 2025
- 400 Pages
Global
From €4405EUR$4,949USD£3,806GBP
- Report
- May 2025
- 87 Pages
Global
From €3500EUR$4,212USD£3,130GBP
- Report
- June 2025
- 280 Pages
Global
From €4446EUR$4,995USD£3,841GBP
- Report
- November 2022
- 154 Pages
Global
From €4451EUR$5,000USD£3,845GBP
- Report
- June 2022
- 1500 Pages
Global
From €3124EUR$3,510USD£2,699GBP
€3472EUR$3,900USD£2,999GBP
- Report
- February 2022
- 360 Pages
United States
From €2884EUR$3,240USD£2,492GBP
€3205EUR$3,600USD£2,768GBP
- Report
- December 2020
- 120 Pages
Global
From €1780EUR$2,000USD£1,538GBP
- Report
- July 2020
- 1200 Pages
Japan
From €2403EUR$2,700USD£2,076GBP
€2670EUR$3,000USD£2,307GBP
- Report
- January 2023
- 189 Pages
Global
From €2991EUR$3,360USD£2,584GBP
€3739EUR$4,200USD£3,230GBP
- Report
- June 2022
- 191 Pages
Global
From €2492EUR$2,800USD£2,153GBP
€3116EUR$3,500USD£2,692GBP
- Report
- August 2022
- 116 Pages
Global
From €4006EUR$4,500USD£3,461GBP
- Report
- March 2024
- 225 Pages
Global
From €7077EUR$7,950USD£6,114GBP
- Report
- November 2023
- 30 Pages
Global
From €2448EUR$2,750USD£2,115GBP
- Report
- November 2023
- 30 Pages
Global
From €2448EUR$2,750USD£2,115GBP
- Report
- May 2023
- 220 Pages
Global
From €2225EUR$2,500USD£1,923GBP

Bevacizumab is a monoclonal antibody used in the treatment of various types of cancer. It is used in combination with other drugs to treat metastatic colorectal cancer, non-small cell lung cancer, glioblastoma, metastatic renal cell carcinoma, and metastatic breast cancer. Bevacizumab works by inhibiting the growth of new blood vessels, which can help slow the growth of tumors. It is administered intravenously and is typically given in combination with other chemotherapy drugs.
Bevacizumab is a widely used drug in the oncology market, and is one of the most prescribed drugs for cancer treatment. It is used in combination with other drugs to treat a variety of cancers, and is often used in combination with chemotherapy. Bevacizumab has been shown to be effective in treating certain types of cancer, and is generally well tolerated.
Some companies in the Bevacizumab market include Genentech, Roche, Pfizer, Merck, and Bristol-Myers Squibb. Show Less Read more